Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.62 |
| ▸ | DRD1 | P21728 | 2/20 | 0.62 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD5 | P21918 | 1/20 | 0.56 |
| ▸ | PNMT | P11086 | 4/20 | 0.55 |
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.50 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.50 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.50 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.50 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.50 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.50 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514775 | 1.00 | DRD2 (0.62) | DRD2DRD1ASIC3DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL453336 | 0.98 | DRD2 (0.61) | DRD2DRD1ASIC3DRD3DRD4 | |
| Bromide SCHEMBL587893 | 0.98 | DRD2 (0.61) | DRD2DRD1ASIC3DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL31336072 | 0.98 | DRD2 (0.61) | DRD2DRD1ASIC3DRD3DRD4 | |
| SCHEMBL470826 | 0.92 | PNMT (0.66) | DRD2DRD1DRD3DRD4DRD5 | |
| Oxalic Acid SCHEMBL6952790 | 0.91 | DRD2 (0.54) | DRD2DRD1ASIC3DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL2675120 | 0.90 | PNMT (0.63) | DRD2DRD1DRD3DRD4DRD5 | |
| Bromide SCHEMBL6190676 | 0.90 | PNMT (0.63) | DRD2DRD1DRD3DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL30955057 | 0.90 | PNMT (0.63) | DRD2DRD1DRD3DRD4DRD5 | |
| SCHEMBL3694554 | 0.88 | DRD2 (0.61) | DRD2DRD1ASIC3DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119685827-B | Environment-friendly composite corrosion and scale inhibitor and preparation method and application thereof | 中国石油化工股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-119685827-A | Environment-friendly composite corrosion and scale inhibitor and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| EP-1831173-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066197-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-22 | — | — | WO | claimed |
| CN-119685827-B | Environment-friendly composite corrosion and scale inhibitor and preparation method and application thereof | 中国石油化工股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-120040420-A | Heterocyclic-pyrazole amine derivatives, preparation method thereof and application thereof in resisting tubercle bacillus infection | 中国医学科学院医药生物技术研究所 | 2025-05-27 | — | — | CN | disclosed |
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-119685827-A | Environment-friendly composite corrosion and scale inhibitor and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-0992502-A1 | 2-(3-Phenyl-2-propenyl)-1,2,3,4-tetrahydro-isochinolin derivatives, process for their preparation and their use as fungicides | HOECHST MARION ROUSSEL (FR) | 2000-04-12 | — | — | EP | disclosed |
| US-5912342-A | SYNTHESIS OF COMBINATORIAL LIBRARIES BY COMPUTER CONTROLLED ROBOT | HEINONEN PETRI (FI) | 1999-06-15 | — | — | US | disclosed |
| EP-0687267-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1995-12-20 | — | — | EP | disclosed |
| EP-0641324-A1 | TETRAHYDRO AND PERHYDRO ISOQUINOLIN DERIVATIVES AND THERAPEUTIC AGENTS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1995-03-08 | — | — | EP | disclosed |
| CN-1085214-A | Tetrahydrochysene one and perhydro isoquinilone derivatives and the therapeutic composition that contains these compounds | BASF AG (DE) | 1994-04-13 | — | — | CN | disclosed |
| WO-1993024461-A1 | TETRAHYDRO AND PERHYDRO ISOQUINOLIN DERIVATIVES AND THERAPEUTIC AGENTS CONTAINING THEM | BASF AKTIENGESELLSCHAFT (DE) | 1993-12-09 | — | — | WO | disclosed |
| US-4717724-A | FUNGICIDES, ANTIPROTOZOA, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-05 | — | — | US | disclosed |
| EP-0121753-A2 | 1-(1,3-Dioxolan-2-ylmethyl)-azoles, their salts, processes for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | DRD2 4503/4885DRD1 3228/4885ASIC3 4591/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | DRD2 4501/4885DRD1 4210/4885ASIC3 3511/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | DRD2 4503/4885DRD1 3228/4885ASIC3 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.